Manufacturers' Data Integrity Problems Remain FDA Investigators' Focus
Executive Summary
US FDA official warns the pharmaceutical industry that investigators will continue to look for data integrity problems during inspections, and discusses “red flags” observed in inspections.
You may also be interested in...
FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
In another show of force on generic drug application quality, US agency says it will not accept applications with major deficiencies caused by a typographical error, even if the sponsor corrects it.
FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
In another show of force on generic drug application quality, US agency says it will not accept applications with major deficiencies caused by a typographical error, even if the sponsor corrects it.
FDA Aligns New Pharmaceutical Inspectorate Into Six Divisions
US FDA’s structure for its new pharmaceutical inspectorate, part of the massive reorganization of the Office of Regulatory Affairs, includes four domestic divisions, a fifth handling foreign inspections and the sixth handling program functions. New staff directory could prove valuable to pharmaceutical companies learning to interact with a very different field organization.